(6) Centers for Disease Control and Prevention. Use of FDA-approved pharmacologic treatments for tobacco dependence. Morbidity and Mortality Weekly Report 2000; 49: 665-668.
Contactos: Mark Polisky
GolinHarris
+1-312-729-4417
mpolisky@golinharris.com
Jennifer May
GlaxoSmithKline
Consumer Healthcare
+1-412-200-3729
jennifer.l.may@gsk.com
Mark Polisky de GolinHarris, +1-312-729-4417, mpolisky@golinharris.com, para GlaxoSmithKline; o Jennifer May de GlaxoSmithKline Consumer Healthcare, +1-412-200-3729, jennifer.l.may@gsk.com
